Innovations in the treatment of severe and complex mental disorders

Abstract

The target group of patients of Community Mental Health Centers are patients with Severe Mental Disorders, such as schizophrenia, bipolar affective disorder, major depressive disorder, patients with dual diagnosis. The treatment of the mentioned disorders is often difficult, but also ineffective. The aim of the study was to analyze scientific publications from the last decade regarding the therapy of severe and complex mental health disorders in order to highlight new treatment methods for the respective categories of patients. Scientific sources published in the last decade from PubMed, Google Scholar, Medscape, were analyzed. Meta-analyses, clinical studies, and relevant review articles were included. Several publications, including meta-analyses, mention the effectiveness of dopamine partial agonists (aripiprazolum, brexpiprazolum, cariprazinum - 3rd generation antipsychotics), in the treatment of deficit symptoms, affective, cognitive, volitional, and craving, which do not yield to therapies previously used for the treatment of severe and complex mental disorders. The mentioned remedies have improved the ability to function independently and the quality of life of patients with severe and complex mental disorders. Their effectiveness may be due to the modulatory action on cerebral dopaminergic receptors. Dopamine partial agonists represent an innovative approach to patients with severe and complex mental disorders. These remedies, especially cariprazinum, have been effective in eradicating “positive”, “negative”, affective, and cognitive symptoms in schizophrenia; in the treatment of uni- and bipolar depression; therapy of patients with dual diagnosis (mental health disorder associated with addiction to psychoactive substances).